IL246968D0 - Targeted tgf-beta inhibition - Google Patents

Targeted tgf-beta inhibition

Info

Publication number
IL246968D0
IL246968D0 IL246968A IL24696816A IL246968D0 IL 246968 D0 IL246968 D0 IL 246968D0 IL 246968 A IL246968 A IL 246968A IL 24696816 A IL24696816 A IL 24696816A IL 246968 D0 IL246968 D0 IL 246968D0
Authority
IL
Israel
Prior art keywords
beta inhibition
targeted tgf
tgf
targeted
inhibition
Prior art date
Application number
IL246968A
Other languages
Hebrew (he)
Inventor
Kin-Ming Lo
Original Assignee
Merck Patent Gmbh
Lo Kin Ming
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US201461938048P priority Critical
Priority to PCT/EP2015/052781 priority patent/WO2015118175A2/en
Application filed by Merck Patent Gmbh, Lo Kin Ming filed Critical Merck Patent Gmbh
Publication of IL246968D0 publication Critical patent/IL246968D0/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177Receptors; Cell surface antigens; Cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/04Drugs for disorders of the respiratory system for throat disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/14Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • C07K14/495Transforming growth factor [TGF]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/33Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
IL246968A 2014-02-10 2016-07-27 Targeted tgf-beta inhibition IL246968D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US201461938048P true 2014-02-10 2014-02-10
PCT/EP2015/052781 WO2015118175A2 (en) 2014-02-10 2015-02-10 TARGETED TGFβ INHIBITION

Publications (1)

Publication Number Publication Date
IL246968D0 true IL246968D0 (en) 2016-09-29

Family

ID=52988007

Family Applications (1)

Application Number Title Priority Date Filing Date
IL246968A IL246968D0 (en) 2014-02-10 2016-07-27 Targeted tgf-beta inhibition

Country Status (15)

Country Link
US (3) US9676863B2 (en)
EP (1) EP3105246A2 (en)
JP (2) JP6731346B2 (en)
KR (1) KR20160119197A (en)
CN (1) CN106103488A (en)
AU (2) AU2015213988B2 (en)
CA (1) CA2934979A1 (en)
CL (1) CL2016002017A1 (en)
IL (1) IL246968D0 (en)
MX (1) MX2016010067A (en)
PE (1) PE20161096A1 (en)
PH (1) PH12016501549A1 (en)
RU (1) RU2016135062A3 (en)
SG (1) SG11201606577YA (en)
WO (1) WO2015118175A2 (en)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016528295A (en) 2013-08-22 2016-09-15 アクセルロン ファーマ, インコーポレイテッド TGF-beta receptor type II mutant and use thereof
WO2015048312A1 (en) 2013-09-26 2015-04-02 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
ES2716685T3 (en) 2014-01-24 2019-06-14 Dana Farber Cancer Inst Inc Antibody molecules for PD-1 and uses thereof
UY35973A (en) 2014-01-31 2015-08-31 Novartis Ag Antibody molecules bind tim-3 and uses thereof
BR112017007379A2 (en) 2014-10-14 2017-12-19 Dana Farber Cancer Inst Inc antibody molecules to pd-l1 and uses thereof
AU2016233495A1 (en) 2015-03-13 2017-10-26 Cytomx Therapeutics, Inc Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of use thereof
JP2018518454A (en) * 2015-04-03 2018-07-12 ゾーマ テクノロジー リミテッド Method for treating cancer using inhibitors of TGF-β and PD-1
EP3736290A1 (en) 2015-05-29 2020-11-11 Agenus Inc. Anti-ctla-4 antibodies and methods of use thereof
US9884900B2 (en) 2015-08-04 2018-02-06 Acceleron Pharma Inc. Methods for treating Janus kinase-associated disorders by administering soluble transforming growth factor beta type II receptor
CA2999756A1 (en) * 2015-09-24 2017-03-30 The University Of North Carolina At Chapel Hill Methods and compositions for reducing metastases
MX2018014047A (en) * 2016-05-17 2019-06-20 Genentech Inc Stromal gene signatures for diagnosis and use in immunotherapy.
JP2019520809A (en) 2016-05-27 2019-07-25 アジェナス インコーポレイテッド Anti-TIM-3 antibody and method of using the same
AU2017310027A1 (en) * 2016-08-12 2019-01-31 Merck Patent Gmbh Combination therapy for cancer
KR20180031174A (en) 2016-09-19 2018-03-28 현대모비스 주식회사 Apparatus and method for recognizing supplementarty traffic signs
EP3526256A1 (en) 2016-10-11 2019-08-21 Agenus Inc. Anti-lag-3 antibodies and methods of use thereof
BR112019011582A2 (en) 2016-12-07 2019-10-22 Agenus Inc. antibodies and their methods of use
EP3551660A1 (en) 2016-12-07 2019-10-16 Agenus Inc. Anti-ctla-4 antibodies and methods of use thereof
WO2018129331A1 (en) * 2017-01-07 2018-07-12 Merck Patent Gmbh Dosing regimens and dosage forms for targeted tgf-b inhibition
GB201700567D0 (en) * 2017-01-12 2017-03-01 Genagon Therapeutics Ab Therapeutic agents
WO2018132739A2 (en) 2017-01-13 2018-07-19 Agenus Inc. T cell receptors that bind to ny-eso-1 and methods of use thereof
KR20190139851A (en) 2017-04-13 2019-12-18 아게누스 인코포레이티드 Anti-CD137 Antibody and Method of Use thereof
US20180355040A1 (en) 2017-05-01 2018-12-13 Agenus Inc. Anti-tigit antibodies and methods of use thereof
CA3063087A1 (en) * 2017-05-09 2018-11-15 Julius Y. STRAUSS Combination pdl1 and tgf-beta blockade in patients with hpv+ malignancies
AU2018264455A1 (en) 2017-05-12 2019-11-14 Jiangsu Hengrui Medicine Co., Ltd. Fusion protein containing TGF-beta receptor and medicinal uses thereof
EP3630836A1 (en) 2017-05-31 2020-04-08 Elstar Therapeutics, Inc. Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof
EP3679062A1 (en) 2017-09-04 2020-07-15 Agenus Inc. T cell receptors that bind to mixed lineage leukemia (mll)-specific phosphopeptides and methods of use thereof
WO2019113464A1 (en) 2017-12-08 2019-06-13 Elstar Therapeutics, Inc. Multispecific molecules and uses thereof
CN111867589A (en) 2018-03-14 2020-10-30 默克专利股份有限公司 Compounds for treating tumors in a subject and uses thereof
WO2019178364A2 (en) 2018-03-14 2019-09-19 Elstar Therapeutics, Inc. Multifunctional molecules and uses thereof
WO2019178362A1 (en) 2018-03-14 2019-09-19 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
WO2019210055A2 (en) 2018-04-26 2019-10-31 Agenus Inc. Heat shock protein-binding peptide compositions and methods of use thereof
WO2019211489A1 (en) 2018-05-04 2019-11-07 Merck Patent Gmbh COMBINED INHIBITION OF PD-1/PD-L1, TGFβ AND DNA-PK FOR THE TREATMENT OF CANCER
AU2019271065A1 (en) * 2018-05-15 2020-11-05 Merck Patent Gmbh Dosing regimens for targeted TGF-B inhibition for use in treating cancer in treatment naive subjects
WO2019222676A1 (en) 2018-05-17 2019-11-21 Bolt Biotherapeutics, Inc. Immunoconjugates
WO2019241353A1 (en) * 2018-06-13 2019-12-19 Merck Patent Gmbh Treatment of stage iii nsclc and mitigation of pathological conditions associated with the treatment
TW202019959A (en) * 2018-06-22 2020-06-01 德商馬克專利公司 Dosing regimens for targeted tgf-β inhibition for use in treating biliary tract cancer
US20200002426A1 (en) 2018-06-29 2020-01-02 Gensun Biopharma, Inc. Antitumor antagonists
TW202019405A (en) * 2018-07-02 2020-06-01 德商馬克專利公司 Combination therapy with targeted tgf-β inhibition for treatment of advanced non-small cell lung cancer
WO2020069372A1 (en) 2018-09-27 2020-04-02 Elstar Therapeutics, Inc. Csf1r/ccr2 multispecific antibodies
WO2020093023A1 (en) 2018-11-01 2020-05-07 Merck Patent Gmbh Anti-tim-3 antibodies
WO2020093024A2 (en) 2018-11-01 2020-05-07 Merck Patent Gmbh Methods of administering anti-tim-3 antibodies
WO2020172605A1 (en) 2019-02-21 2020-08-27 Elstar Therapeutics, Inc. Antibody molecules that bind to nkp30 and uses thereof
WO2020172598A1 (en) 2019-02-21 2020-08-27 Elstar Therapeutics, Inc. Multifunctional molecules that bind to t cells and uses thereof to treat autoimmune disorders
WO2020172571A1 (en) 2019-02-21 2020-08-27 Elstar Therapeutics, Inc. Multifunctional molecules that bind to t cell related cancer cells and uses thereof
WO2020190734A1 (en) 2019-03-15 2020-09-24 Bolt Biotherapeutics, Inc. Immunoconjugates targeting pd-l1

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4314801A (en) 2000-02-11 2001-08-20 Lexigen Pharm Corp Enhancing the circulating half-life of antibody-based fusion proteins
JP4234438B2 (en) 2001-03-07 2009-03-04 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトングMerck Patent Gesellschaft mit beschraenkter Haftung Expression technology of protein containing hybrid isotype antibody part
WO2002079415A2 (en) 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
JP2005112812A (en) * 2003-10-09 2005-04-28 Univ Kansai Medical Antibody specific to phosphorylation site and screening method using the same
EP1708712A1 (en) * 2003-12-24 2006-10-11 Scios, Inc. Treatment of malignant gliomas with tgf-beta inhibitors
CA3018525A1 (en) 2005-07-01 2007-01-11 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
DK2376535T3 (en) 2008-12-09 2017-06-12 F Hoffmann-La Roche Ag ANTI-PD-L1 ANTIBODIES AND THEIR USE TO PROMOTE T CELL FUNCTION
ES2638521T3 (en) * 2010-03-05 2017-10-23 The Johns Hopkins University Compositions and methods for antibodies and immunomodulatory fusion proteins directed against targets
CN103842030B (en) * 2011-08-01 2018-07-31 霍夫曼-拉罗奇有限公司 Use the method for PD-1 axis binding antagonists and mek inhibitor treating cancer
CN103987405B (en) * 2011-11-28 2017-03-29 默克专利股份公司 Anti- PD L1 antibody and application thereof
CA2947354A1 (en) * 2012-04-30 2013-11-07 Biocon Limited Targeted/immunomodulatory fusion proteins and methods for making same

Also Published As

Publication number Publication date
WO2015118175A2 (en) 2015-08-13
PE20161096A1 (en) 2016-10-22
MX2016010067A (en) 2016-10-07
PH12016501549A1 (en) 2016-10-03
JP6731346B2 (en) 2020-07-29
JP2020174674A (en) 2020-10-29
CL2016002017A1 (en) 2017-06-09
JP2017506217A (en) 2017-03-02
RU2016135062A3 (en) 2018-12-12
CA2934979A1 (en) 2015-08-13
EP3105246A2 (en) 2016-12-21
RU2016135062A (en) 2018-03-15
AU2019246876A1 (en) 2019-10-31
WO2015118175A3 (en) 2015-10-08
US9676863B2 (en) 2017-06-13
KR20160119197A (en) 2016-10-12
AU2015213988A1 (en) 2016-07-07
SG11201606577YA (en) 2016-09-29
AU2015213988B2 (en) 2019-07-11
CN106103488A (en) 2016-11-09
US20200055949A1 (en) 2020-02-20
US20150225483A1 (en) 2015-08-13
US20180002436A1 (en) 2018-01-04

Similar Documents

Publication Publication Date Title
HRP20190575T1 (en) Immunomodulators
IL252853D0 (en) Immunomodulators
ZA201702484B (en) Immunomodulators
HK1217861A1 (en) Wifi-coordinated laa-lte
PL3180060T3 (en) Device
GB2513048B (en) Device proximity
GB201413019D0 (en) Beyond 1B
IL251813D0 (en) Combination
AU356990S (en) Vehicle
SG11201606577YA (en) TARGETED TGFβ INHIBITION
SG11201606340WA (en) Device
GB201410907D0 (en) No details
AU358957S (en) Vehicle
EP2982585A4 (en) Vehicle
IL246785D0 (en) Benzimidazol-2-amines as midh1 inhibitors
EP2982586A4 (en) Vehicle
GB201407606D0 (en) Electroluminescent device
GB201421133D0 (en) Electroluminescent device
HK1226398A1 (en) Benzimidazol-2-amines as midh1 inhibitors
GB201419094D0 (en) Anti-TIM-3-antibodies
IL250891D0 (en) Smyd inhibitors
AU359933S (en) Automobile
IL248895D0 (en) Phosphatidylinositol -kinase inhibitors
HK1226390A1 (en) Condensed 5-oxazolidinone derivative
GB2528557B (en) Soundbar